The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
Abstract
Purpose: A phase III, multicenter, randomized study compared conventional dosing of fluorouracil (FU) plus folinic acid with pharmacokinetically guided FU dose adjustment in terms of response, tolerability, and survival. Patients and Methods: Two hundred eight patients with measurable metastatic colorectal cancer were randomly assigned to one of two arms: arm A (104 patients; 96 assessable), in which the FU dose was calculated based on body-surface area; and arm B (104 patients; 90 assessable), in which the FU dose was individually determined using pharmacokinetically guided adjustments. The initial regimen was 1,500 mg/m 2 FU plus 200 mg/m 2 folinic acid infusion during a continuous 8-hour period administered once weekly. FU doses were adjusted weekly in arm B based on a single-point measurement of FU plasma concentrations at steady state until the therapeutic range (targeted area under the curve 20-25 mg·h·L−1) previously established in other studies was reached. Results: An intent-to-treat analysis of the 208 patients showed the objective response rate was 18.3% in arm A and 33.7% in arm B (P = .004). Median overall survival was 16 months in arm A and 22 months in arm B (P = .08). The mean FU dose throughout treatment was 1,500 mg/m 2/wk in arm A and 1,790 ± 386 mg/m 2/wk (range, 900 to 3,300 mg/m 2/wk) in arm B. Toxic adverse effects were significantly more frequent and severe in arm A compared with arm B (P = .003). Conclusion: Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities. These results support the value of pharmacokinetically guided management of FU dose in the treatment of metastatic colorectal patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Fluorouracil: biochemistry and pharmacology.
Pinedo, H. M., & Peters, G. F. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1653 · Cited by 834
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773
Diasio, R. B., Beavers, T. L., & Carpenter, J. T. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113308 · Cited by 503
Population study of dihydropyrimidine dehydrogenase in cancer patients.
Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renée, N., Schneider, M., Demard, F., & Milano, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2248 · Cited by 436
Poon, M. A., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Tschetter, L. K., Levitt, R., Kardinal, C. G., & Mailliard, J. A. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.1967 · Cited by 375
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351
Morel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., & Gamelin, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0327 · Cited by 236
Self-citationFleming, R. A., Milano, G. A., Thyss, A., Étienne-Grimaldi, M.-C., Renée, N., Schneider, M., & Demard, F. (1992) · PubMed · Cited by 235
Gamelin, E. C., Danquechin-Dorval, E. M., Dumesnil, Y. F., Maillart, P. J., Goudier, M. J., Burtin, P. C., Delva, R. G., Lortholary, A. H., Gesta, P. H., & Larra, F. G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960201)77:3<441::aid-cncr4>3.0.co;2-n · Cited by 218
Self-citationArdalan, B., Chua, L., Tian, E. M., Reddy, K. R., Sridhar, K., Benedetto, P. W., Richman, S. P., Legaspi, A., Waldman, S., & Morrell, L. M. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.625 · Cited by 197
Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Diasio, R. B., & Johnson, M. R. (1999) · PubMed · Cited by 113
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency
Kuilenburg, A. B. P., ABREU, R. A. D., & Gennip, A. H. (2003) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456303321016150 · Cited by 95
Arbuck (1989) · doi:10.1002/1097-0142(19890315)63:6+<1036::aid-cncr2820631309>3.0.co;2-k
Cited by
Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
IMAMURA, Y., MUKOHARA, T., SHIMONO, Y., FUNAKOSHI, Y., CHAYAHARA, N., TOYODA, M., KIYOTA, N., TAKAO, S., KONO, S., NAKATSURA, T., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.3767 · Cited by 845
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.911 · Cited by 694
Caudle, K. E., Thorn, C. F., Klein, T. E., Swen, J. J., McLeod, H. L., Diasio, R. B., & Schwab, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.172 · Cited by 330
Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics
Paci, A., Veal, G., Bardin, C., Levêque, D., Widmer, N., Beijnen, J., Astier, A., & Chatelut, E. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.014 · Cited by 260
Guidance on the management of diarrhoea during cancer chemotherapy
Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., Wedlake, L., Bridgewater, J., Glynne-Jones, R., Allum, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70006-3 · Cited by 257
Metadata
- Authors
- Gamelin, E., Delva, R., Jacob, J., Merrouche, Y., Raoul, J. L., Pezet, D., Dorval, E., Piot, G., Morel, A., & Boisdron-Celle, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-01
- Volume
- 26
- Issue
- 13
- Pages
- 2099-2105
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142287269
- Cited by
- 346
- References
- 17
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.